|
市場調査レポート
競合分析：血液凝固因子
Competitor Analysis: Coagulation Factors
|
Abstract
Report Statistics
- Pages: 126
- Release Date: October of 2009
- Format: PDF
Product description
The present Competitive Intelligence Report about Coagulation Factors provides
a competitor evaluation in the field of plasma-derived and recombinant
coagulation factors for topical or systemic administration to treat hereditary
or acquired coagulation disorders as of October 2009. Purchase of the
downloadable pdf report includes a 6-month online access to the data of the
report and any updates since the publication date. Credentials to access the
database will be sent by e-mail and allow online work with the project data to
print or export an individual report.
The market size of recombinant and plasma-derived coagulation factor products
exceeded US$ 7.5 bln in 2008, the majority (US$ 5.5 bln) generated by
recombinant proteins. Replacement of plasma-derived coagulation factors by
marketed recombinant molecules is ongoing and will further increase by new
recombinant coagulation factors in development. In light of ongoing expiration
of substance patents, about 40 new recombinant coagulation factor projects are
in the pipeline indicating a changing marketplace over the next decade. New
players are competing and will challenge established manufacturers and
marketers of coagulation factor products.
Apart from recombinant products, plasma-derived coagulation factors still play
a considerable role, albeit bovine derived products are considerably being
challenged by human recombinant and plasma-derivd products. Coagulation
factors not only are being used for systemic treatment of hereditary
coagulation factor deficiencies, but also for topical or systemic treatment of
bleedings.
The report includes a compilation of current active projects in research and
development of topical and systemic coagulation factors obtained by
purification of human plasma or by recombinant DNA technology. In addition,
the report lists company-specific R&D pipelines of coagulation factors.
Competitor projects are listed in a tabular format providing information on:
- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.
Table of Contents
Index
- Coagulation Factor VIII
- Coagulation Factor IX
- Coagulation Factor VII
- Von Willebrand Factor (vWF)
- Fibrinogen
- Coagulation Factors V and XI
- Coagulation Factor X
- Coagulation Factor XIII
- Topical Fibrinogen and Thrombin Products
- Topical Thrombin Products
- Prothrombin Complex Concentrates
Corporate Coagulation Factor Product and R&D Pipelines
- About La Merie
- Corporate Coagulation Factor Product and R&D Pipelines
- Abraxis Biosciences
- Amsterdam Molecular Therapeutics
- Angiotech
- Apitope
- Asklepios Biopharmaceutical
- Baxter
- Bayer Schering Pharma
- Bio Products Laboratory (BPL)
- Biogen Idec
- Biotest
- Biovitrum
- Catalyst Biosciences
- China Biologic Products
- Crucell
- CSL
- Ethicon (J&J)
- Genzyme
- Green Cross
- Grifols
- GTC Biotherapeutics
- Haemacure
- Inspiration Biopharmaceuticals
- Intas Biopharmaceuticals
- Ipsen
- Jerini
- Kaketsuken
- Kamada
- Kedrion
- King Pharmaceuticals
- LFB
- Lipoxen
- Maxygen
- MDRNA
- MediVas
- Mochida Pharmaceutical
- National Bioproducts Institute (NBI)
- Nautilus Biotech (HanAll Pharmaceuticals)
- Nektar Therapeutics
- Neose Technologies
- Novo Nordisk
- Nycomed
- Octapharma
- Oxford Biomedica
- Pharming
- ProFibrix
- ProGenetics
- PROLOR Biotech
- Recoly
- Roche
- Sanquin
- Shanghai RAAS
- Sinobiomed
- SK Chemicals
- Talecris Biotherapeutics
- Thrombotargets
- VIRxSYS
- Wyeth
- Zymogenetics
|
